Loading...

Shanghai Henlius Biotech, Inc.

2696.HK•HKSE
Healthcare
Biotechnology
HK$52.30
HK$-3.15(-5.68%)

Shanghai Henlius Biotech, Inc. (2696.HK) Stock Overview

Explore Shanghai Henlius Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 75.7/100

Key Financials

Market Cap28.4B
P/E Ratio31.62
EPS (TTM)$1.65
ROE0.29%
Fundamental Analysis

AI Price Forecasts

1 Week$50.13
1 Month$37.06
3 Months$41.55
1 Year Target$37.66

2696.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Shanghai Henlius Biotech, Inc. (2696.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 55.42, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $37.66.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 31.62 and a market capitalization of 28.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

55.42RSI (14)
2.60MACD
36.11ADX
Revenue Growth
6.11%
↑ 6.11%
Profit Growth
HK$1.51
↑ 50.26%
EPS Growth
HK$1.51
↑ 51.00%
Operating Margin
15.14%
↑ 48.67%
ROE
29.35%
↑ 50.26%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 2696.HKAnalyst Recommendations details for 2696.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

CEO

Jun Zhu

Employees

3,515

Headquarters

Innov Tower (Capitaland Building), Shanghai

Founded

2019

Frequently Asked Questions

;